Related references
Note: Only part of the references are listed.Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling
Gunther Zimmermann et al.
NATURE (2013)
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Daniel Martinez Molina et al.
SCIENCE (2013)
Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras
Jin Xu et al.
BLOOD (2012)
The atypical E2F family member E2F7 couples the p53 and RB pathways during cellular senescence
Ozlem Aksoy et al.
GENES & DEVELOPMENT (2012)
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge et al.
LANCET ONCOLOGY (2012)
Specific CLK Inhibitors from a Novel Chemotype for Regulation of Alternative Splicing
Oleg Fedorov et al.
CHEMISTRY & BIOLOGY (2011)
Crystal structure of human MTH1 and the 8-oxo-dGMP product complex
Linda M. Svensson et al.
FEBS LETTERS (2011)
An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance
Johannes Zuber et al.
GENES & DEVELOPMENT (2011)
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
J. Jean Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Enhanced elimination of oxidized guanine nucleotides inhibits oncogenic RAS-induced DNA damage and premature senescence
P. Rai et al.
ONCOGENE (2011)
RAS oncogenes: weaving a tumorigenic web
Yuliya Pylayeva-Gupta et al.
NATURE REVIEWS CANCER (2011)
ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time
David E. Gerber et al.
CANCER CELL (2010)
Small-molecule inhibition of APT1 affects Ras localization and signaling
Frank J. Dekker et al.
NATURE CHEMICAL BIOLOGY (2010)
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
James E. Butrynski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
David A. Barbie et al.
NATURE (2009)
Continuous elimination of oxidized nucleotides is necessary to prevent rapid onset of cellular senescence
Priyamvada Rai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Two distinct pathways of cell death triggered by oxidative damage to nuclear and mitochondrial DNAs
Sugako Oka et al.
EMBO JOURNAL (2008)
RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels
Nicholas Yagoda et al.
NATURE (2007)
An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
Helen Y. Zou et al.
CANCER RESEARCH (2007)
Contribution of hMTH1 to the maintenance of 8-oxoguanine levels in lung DNA of non-small-cell lung cancer patients
E Speina et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
A small molecule-kinase interaction map for clinical kinase inhibitors
MA Fabian et al.
NATURE BIOTECHNOLOGY (2005)
Spontaneous tumorigenesis in mice defective in the MTH1 gene encoding 8-oxo-dGTPase
T Tsuzuki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
